Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2013

Open Access 01-12-2013 | Research

The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases

Authors: Sunil Rodger, Hanns Lochmüller, Adrian Tassoni, Kathrin Gramsch, Kirsten König, Kate Bushby, Volker Straub, Rudolf Korinthenberg, Janbernd Kirschner

Published in: Orphanet Journal of Rare Diseases | Issue 1/2013

Login to get access

Abstract

Background

Rare diseases pose many research challenges specific to their scarcity. Advances in potential therapies have made it more important than ever to be able to adequately identify not only patients with particular genotypes (via patient registries) but also the medical professionals who provide care for them at particular specialist centres of expertise and who may be competent to participate in trials. Work within the neuromuscular field provides an example of how this may be achieved.

Methods

This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies.

Results

285 CTSR-registered centres, reporting 35,495 neuromuscular patients, are described alongside an analysis of their provision for DMD. Site characteristics vary by country: the average number of DMD patients seen per site in the United States (96) is more than in Germany (25), and paediatric/adult breakdown is also markedly distinct. Over 70% of sites have previous trial experience, with a majority including a Clinical Trials Unit. Most sites also have MLPA diagnostic capability and access to a range of medical specialists. However, in the three countries reporting most sites (US, the UK and Germany), few had access to all core DMD specialists internally. Over 60% of sites did not report any form of transition arrangement.

Conclusions

Registries of care and trial sites have significant utility for research into rare conditions such as neuromuscular diseases, demonstrated by the significant engagement by industry and other researchers with the CTSR. We suggest that this approach may be applicable to other fields needing to identify centres of expertise with the potential to carry out clinical research and engage in clinical trials. Such registries also lend themselves to the developing context of European Reference Networks (ERNs), which seek to build networks of centres of expertise which fit specific criteria, and which may themselves aid the sustainability of such registries. This is particularly the case given the utility of registries such as the CTSR in enabling networks of best-practice care centres.
Appendix
Available only for authorised users
Literature
3.
go back to reference Taruscio D, Gainotti S, Vittozzi L, Bianchi F, Ensini M, Posada M: EPIRARE survey on activities and needs of rare disease registries in the European Union. Orphanet J Rare Dis. 2012, 7: A22. 10.1186/1750-1172-7-S2-A22.PubMedCentralCrossRef Taruscio D, Gainotti S, Vittozzi L, Bianchi F, Ensini M, Posada M: EPIRARE survey on activities and needs of rare disease registries in the European Union. Orphanet J Rare Dis. 2012, 7: A22. 10.1186/1750-1172-7-S2-A22.PubMedCentralCrossRef
13.
go back to reference Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010, 9: 77-93. 10.1016/S1474-4422(09)70271-6.PubMedCrossRef Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010, 9: 77-93. 10.1016/S1474-4422(09)70271-6.PubMedCrossRef
14.
go back to reference Abbott D, Carpenter J, Bushby K: Transition to adulthood for young men with Duchenne muscular dystrophy: research from the UK. Neuromuscul Disord. 2012, 22: 445-446. 10.1016/j.nmd.2012.02.004.PubMedCrossRef Abbott D, Carpenter J, Bushby K: Transition to adulthood for young men with Duchenne muscular dystrophy: research from the UK. Neuromuscul Disord. 2012, 22: 445-446. 10.1016/j.nmd.2012.02.004.PubMedCrossRef
16.
go back to reference Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S: Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010, 9: 177-189. 10.1016/S1474-4422(09)70272-8.PubMedCrossRef Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S: Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010, 9: 177-189. 10.1016/S1474-4422(09)70272-8.PubMedCrossRef
18.
go back to reference Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, Roy A, Chamova T, Guergueltcheva V, Korngut L: The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat. 2013, 34: 1449-1457. 10.1002/humu.22390.PubMedCrossRef Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, Roy A, Chamova T, Guergueltcheva V, Korngut L: The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat. 2013, 34: 1449-1457. 10.1002/humu.22390.PubMedCrossRef
19.
go back to reference Tuffery-Giraud S, Beroud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L, Moizard MP, Bernard R, Cossee M, Boisseau P: Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat. 2009, 30: 934-945. 10.1002/humu.20976.PubMedCrossRef Tuffery-Giraud S, Beroud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L, Moizard MP, Bernard R, Cossee M, Boisseau P: Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat. 2009, 30: 934-945. 10.1002/humu.20976.PubMedCrossRef
21.
go back to reference Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen G-J, den Dunnen JT: Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat. 2009, 30: 293-299. 10.1002/humu.20918.PubMedCrossRef Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen G-J, den Dunnen JT: Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat. 2009, 30: 293-299. 10.1002/humu.20918.PubMedCrossRef
22.
go back to reference Norwood FLM, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V: Prevalence of genetic muscle disease in northern england: in-depth analysis of a muscle clinic population. Brain. 2009, 132: 3175-3186. 10.1093/brain/awp236.PubMedCentralPubMedCrossRef Norwood FLM, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V: Prevalence of genetic muscle disease in northern england: in-depth analysis of a muscle clinic population. Brain. 2009, 132: 3175-3186. 10.1093/brain/awp236.PubMedCentralPubMedCrossRef
23.
go back to reference Scully MA, Cwik VA, Marshall BC, Ciafaloni E, Wolff JM, Getchius TS, Griggs RC: Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?. Neurol. 2013, 80: 583-589. 10.1212/WNL.0b013e318282334e.CrossRef Scully MA, Cwik VA, Marshall BC, Ciafaloni E, Wolff JM, Getchius TS, Griggs RC: Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?. Neurol. 2013, 80: 583-589. 10.1212/WNL.0b013e318282334e.CrossRef
Metadata
Title
The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases
Authors
Sunil Rodger
Hanns Lochmüller
Adrian Tassoni
Kathrin Gramsch
Kirsten König
Kate Bushby
Volker Straub
Rudolf Korinthenberg
Janbernd Kirschner
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2013
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-8-171

Other articles of this Issue 1/2013

Orphanet Journal of Rare Diseases 1/2013 Go to the issue